The statistical analysis of cost-effectiveness data is becoming increasingly important within health and medical research. Statistical Analysis of Cost-Effectiveness Data provides a practical book that synthesises the huge amount of research that has taken place in the area over the last two decades. Comprising an up-to-date overview of the statistical analysis of cost-effectiveness data, the book is supported by numerous worked examples from the author’s own experience. It has been written in a style suitable for medical statisticians and health care professionals alike. Key features include: an overview of statistical methods used in the analysis of cost-effectiveness data. coverage of Bayesian methodology. illustrated throughout by worked examples using real data. suitability for health care professionals with limited statistical knowledge. discussion of software used for data analysis. An essential reference for biostatisticians and health economists engaged in cost-effectiveness analysis of health-care interventions, both in academia and industry. Also of interest to graduate students of biostatistics, public health and economics.

The third volume in the Handbooks in Health Economic Evaluation series, this book provides the reader with a comprehensive set of instructions and examples of how to perform an economic evaluation of a health intervention. It focuses solely on cost-effectiveness analysis in health care. The book is developed out of the Advanced Methods of Cost-Effectiveness Analysis course taught at the University of Oxford and the four main sections mirror the four principal components of the course: Outcomes, Costs, Modelling using decision tress and Markov models, and Presenting cost-effectiveness results.&L ABOUT THE SERIES Series editors Alastair Gray and Andrew Briggs Economic evaluation of health intervention is a growing specialist field, and this series of practical handbooks tackles, in depth, topics superficially addressed in more general economics books. Each volume includes illustrative material, case histories and worked examples to encourage the reader to apply the methods discussed, with supporting material provided online. The series is for health economists in academia, the pharmaceutical industry and the health sector, those on advanced health economics courses, and health researchers in associated fields.

Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity’s Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.

4th-7th eds. contain a special chapter on The role and function of the thesaurus in education, by Frederick Goodman.